---
title: "Effect of London’s Ultra Low Emission Zone on PM2.5 and respiratory prescribing: synthetic control"
id: "medrxiv-0-the-impact-of-london-s-ultra-low-emission-zone-on-respiratory-prescribing-a"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-the-impact-of-london-s-ultra-low-emission-zone-on-respiratory-prescribing-a"
content_type: "clinical_feed_article"
specialty: "Pulmonology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.27.26361515v1?rss=1"
published_at: "2026-09-01T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Effect of London’s Ultra Low Emission Zone on PM2.5 and respiratory prescribing: synthetic control
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-the-impact-of-london-s-ultra-low-emission-zone-on-respiratory-prescribing-a
- **Specialty:** [Pulmonology](https://medichelpline.com/clinical-feed/pulmonology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.27.26361515v1?rss=1)
- **Published At:** 2026-09-01T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This preprint assessed the causal impact of all three stages of London’s **Ultra Low Emission Zone (ULEZ)** on air quality and respiratory medication prescribing using a generalised synthetic control method applied at the general practice level. - Air quality was measured via **PM2.5** levels; respiratory outcomes used prescribing records for bronchodilators and inhaled corticosteroids (quantity and average daily quantity, ADQ). - Stage 1 of the ULEZ was associated with a statistically significant but very small **0.77% reduction in PM2.5**, with no detectable change in prescribing patterns at general practice level. - Stage 2 showed a paradoxical **2.69% increase in PM2.5**. Concurrently there was a **4.44% decrease in inhaled corticosteroid quantity** but a **12.51% increase in inhaled corticosteroid ADQ**, interpreted as potential worsening of disease severity among existing patients rather than case numbers increasing. - Stage 3 produced a **2.69% reduction in PM2.5** and a modest **2.18% decrease in bronchodilator ADQ** usage. - Spillover effects outside the ULEZ boundary were statistically significant but quantitatively negligible. - Overall, across all three stages the ULEZ produced minimal effects on both measured air quality (PM2.5) and respiratory prescribing in this analysis. - Authors conclude the zone’s measured impacts are considerably smaller than some prior reports, and they suggest that ULEZ implementation may need integration with broader policy measures to achieve meaningful public health improvement. - Data used were publicly available from sources including English prescribing data, Public Health England (Fingertips), GP data hub (QOF), and Freedom of Information returns from Transport for London. The manuscript is a preprint and has not been peer reviewed.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=u0v654ZJXEOCmvWb2oZ2rE8Tqf.c5NrWd1bIYhnQCj8-1788274932.132206-1.2.1.1-kFdLdjBlyOotIc.Es4UA.tsAPJyYkHVVVTrrnP4UyLI8B6RDyaui.cPzymMWusTf) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.27.26361515v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # The impact of London's Ultra Low Emission Zone on respiratory prescribing: a synthetic control study [ View ORCID Profile](http://orcid.org/0009-0007-0337-0807)George Huw Williams, [ View ORCID Profile](http://orcid.org/0000-0002-2972-7911)Thomas Allen doi: https://doi.org/10.64898/2026.08.27.26361515 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. George Huw Williams University of Manchester * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=George%2BHuw%2BWilliams%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Williams%20GH&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGeorge%2BHuw%2BWilliams%2B) * [ORCID record for George Huw Williams](http://orcid.org/0009-0007-0337-0807 "Open in new tab") * For correspondence: georgewilliams1257@outlook.com Thomas Allen University of Manchester * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thomas%2BAllen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Allen%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AThomas%2BAllen%2B) * [ORCID record for Thomas Allen](http://orcid.org/0000-0002-2972-7911 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.27.26361515v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1289726/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.27.26361515v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1289726/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.27.26361515v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1289726/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.27.26361515v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1289726/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.27.26361515v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1289726/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Urban air pollution remains a significant public health concern, contributing to premature deaths and adverse health outcomes. However, there is little causal research evaluating the effectiveness of policies designed to improve air quality. This study assesses the impact of all three stages of London's Ultra Low Emission Zone (ULEZ) on air pollution, via PM2.5 levels, and respiratory health, via prescription records for bronchodilator and respiratory corticosteroid medications. Analyses are at general practice level, using a generalised synthetic control method to estimate causal impacts. Stage 1 was associated with a statistically significant but negligible 0.77% reduction in PM2.5 levels, with no corresponding change in prescribing. Stage 2 produced a paradoxical 2.69% increase in PM2.5, alongside a 4.44% decrease in inhaled corticosteroid quantity but a 12.51% increase in average daily quantity (ADQ) usage, suggesting a worsening of disease severity among existing patients. Stage 3 yielded a 2.69% PM2.5 reduction and a modest 2.18% decrease in bronchodilator ADQ usage. Spillover effects beyond the ULEZ boundary were statistically significant, but negligible. We find overall that the ULEZ had minimal effects on both air quality and respiratory prescribing across all three stages. These findings provide new insights into the effectiveness of ULEZ policies in reducing air pollution and its associated health impacts, suggesting the zone's effects are considerably smaller than previously reported, and that integration with broader policy measures may be necessary to achieve meaningful public health gains. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All patient data used is publicly available and accessible from the sources listed in the data bibliography. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data analysed in the present study is available online at the sources listed in the data bibliography or data availability links. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.27.26361515v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.26.26361384v1 "Workforce Cost Absorption among Community Health Promoters in Fragmented Maternal Nutrition and Social Protection Systems: A Qualitative Study Across Three Kenyan Settings")[Next ](https://www.medrxiv.org/content/10.1101/2025.10.30.25339159v2 "Gender-associated differences in serum metabolite profiles among patients with Parkinson's Disease") Posted September 01, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.27.26361515v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/01/2026.08.27.26361515.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.27.26361515v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/01/2026.08.27.26361515.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) The impact of London's Ultra Low Emission Zone on respiratory prescribing: a synthetic control study George Huw Williams, Thomas Allen medRxiv 2026.08.27.26361515; doi: https://doi.org/10.64898/2026.08.27.26361515 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.27.26361515v1%26text%3DThe%2520impact%2520of%2520London%2527s%2520Ultra%2520Low%2520Emission%2520Zone%2520on%2520respiratory%2520prescribing%253A%2520a%2520synthetic%2520control%2520study "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.27.26361515v1%26t%3DThe%2520impact%2520of%2520London%2527s%2520Ultra%2520Low%2520Emission%2520Zone%2520on%2520respiratory%2520prescribing%253A%2520a%2520synthetic%2520control%2520study "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.27.26361515v1%26title%3DThe%2520impact%2520of%2520London%2527s%2520Ultra%2520Low%2520Emission%2520Zone%2520on%2520respiratory%2520prescribing%253A%2520a%2520synthetic%2520control%2520study%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.27.26361515v1%26title%3DThe%2520impact%2520of%2520London%2527s%2520Ultra%2520Low%2520Emission%2520Zone%2520on%2520respiratory%2520prescribing%253A%2520a%2520synthetic%2520control%2520study "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.27.26361515) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.27.26361515v1&count=horizontal&via=&text=The%20impact%20of%20London%27s%20Ultra%20Low%20Emission%20Zone%20on%20respiratory%20prescribing%3A%20a%20synthetic%20control%20study&counturl=www.medrxiv.org/content/10.64898/2026.08.27.26361515v1 "Tweet This") ## Subject Area * [Epidemiology ](https://www.medrxiv.org/collection/epidemiology) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (613) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (895) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (326) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4768) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (474) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (406) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (643) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1613) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15831) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1194) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6981) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (727) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1057) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4977) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1425) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1734) * [Hematology](https://www.medrxiv.org/collection/hematology) (580) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1333) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16241) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1160) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (663) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (151) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (720) * [Neurology](https://www.medrxiv.org/collection/neurology) (7189) * [Nursing](https://www.medrxiv.org/collection/nursing) (363) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1072) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1230) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1001) * [Oncology](https://www.medrxiv.org/collection/oncology) (3570) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1036) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (393) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (446) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (465) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (702) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1772) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (733) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (759) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5830) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9687) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2386) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1432) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1239) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (633) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (765) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (576) * [Surgery](https://www.medrxiv.org/collection/surgery) (766) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (302) * [Urology](https://www.medrxiv.org/collection/urology) (286) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of the authors. TRiP reviews are part of a peer review pilot project in which participating organizations post peer reviews of manuscripts they are evaluating _There is no TRiP material for this paper._ Community Reviews medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Community reviews for this article: _There are no community reviews for this paper._ Automated Evaluations Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv. Automated Evaluations: _There are no automated evaluations for this paper._ Blog/Media Links medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Video medRxiv partners with conferences and institutions to display recordings of talks and seminars related to preprints. These are posted with the consent of the authors. Video: _There are no videos for this paper._ Powered by [![Hypothes.is logo](https://connect.biorxiv.org/eval/hypothesis.png)](https://web.hypothes.is/) Powered by [![Altmetric logo](https://connect.biorxiv.org/eval/altmetric.png)](https://www.altmetric.com/) ## Follow this preprint X You can now receive automatic notifications when a preprint is revised, withdrawn, commented on, peer reviewed, or published in a journal. Select the events you would like to follow below and click "Submit". To see all of the pr
## Related Clinical Research

- [Which interventions affect biological aging? Epigenetic study finds diet, exercise, and some drugs](https://medichelpline.com/clinical-feed/medical-news-today-0-what-can-and-can-t-slow-down-aging-new-study-offers-clues.md)
- [Intensive blood pressure control linked to 15% lower 7-year dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-intensive-blood-pressure-control-cuts-7-year-dementia-risk-by-15-study-finds.md)
- [SniffCell: Cell-type-resolved somatic variant discovery from bulk long-read sequencing](https://medichelpline.com/clinical-feed/medrxiv-11-cell-type-resolved-somatic-variant-discovery-from-bulk-long-read-sequencing.md)
- [AI-Based Early Detection of Polycystic Ovary Syndrome Using Follicle Count and Machine Learning](https://medichelpline.com/clinical-feed/medrxiv-0-ai-driven-early-detection-of-polycystic-ovary-syndrome-via-follicle-count.md)
- [Nonlinear association of sleep quality (PSQI) with type 2 diabetes prevalence in community chronic](https://medichelpline.com/clinical-feed/plos-one-18-nonlinear-relationship-between-sleep-quality-and-prevalence-of-type-2-diabetes.md)

## Navigation
- [← Back to Pulmonology Feed](https://medichelpline.com/clinical-feed/pulmonology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.